Core Insights - Novo Nordisk's weight loss drug Wegovy faces unexpected market challenges due to the launch of a generic version by Hims & Hers Health, priced significantly lower than the original [1][3] - The introduction of Hims' generic version has sparked intense debates regarding drug patent protection and regulatory frameworks [1] - Novo Nordisk plans to take legal and regulatory actions to protect its intellectual property and the integrity of the U.S. drug approval framework [1] Pricing and Market Impact - Hims' generic version is priced at $49 for the first month and $99 thereafter, compared to Novo Nordisk's starting price of $149 [1] - Following the announcement, Novo Nordisk's ADR shares dropped over 8%, while competitor Eli Lilly's shares fell by 7.1% [1] Product Formulation and Technology Dispute - The core dispute between the two companies revolves around the drug formulation technology, with Novo Nordisk claiming its proprietary technology protects the active ingredient semaglutide from stomach acid [7] - Hims asserts that its formulation also protects the active ingredient during digestion, claiming it is not a direct copy of Wegovy [8] Market Position and Revenue Expectations - Despite the controversy, analysts had projected that Novo Nordisk's new tablet could generate $1.3 to $1.35 billion in revenue in its first year [9] - Over 170,000 patients have started using the drug since its launch in January, marking it as one of the most successful drug launches recently [9] Competitive Landscape - Novo Nordisk is losing its competitive edge in the obesity market, facing challenges not only from Eli Lilly but also from remote healthcare companies like Hims selling generic drugs [9] - Analysts expect that other new weight loss products, including one being developed by Eli Lilly, may also become targets for generic versions [10]